Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
- 2023
-
1. Planning and response to COVID-19: lessons from China and South-East Asia
- Prof. Annelies Wilder-Smith
- 2022
-
2. The emergence of the SARS-CoV-2 Omicron variant
- Prof. Emma Thomson
-
3. How is Omicron different?
- Prof. Emma Thomson
- 2021
-
5. Potential of ‘long-COVID’ in triggering chronic co-pathologies
- Dr. İmdat Eroğlu
-
6. SARS-CoV-2 monoclonal antibody testing in vivo
- Prof. Michael Diamond
-
7. mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals
- Prof. E. John Wherry
-
8. SARS-CoV-2 variants: implications for immunity and vaccine development
- Prof. Danny Altmann
-
10. SARS-COV-2 human monoclonal antibody therapy update
- Prof. James Crowe
-
11. Emergence of blood clotting disorders resulting from COVID vaccines inoculations
- Prof. Dr. Sabine Eichinger
-
12. SARS-CoV-2 evolution within and between individuals
- Prof. Katia Koelle
-
13. Identifying SARS-CoV-2 proteases
- Prof. Dr. Christa E. Müller
- Prof. Dr. Michael Gütschow
-
14. Genetic surveillance and the emergence of SARS-CoV-2 variants
- Prof. Emma Thomson
-
15. The COVID-19 outbreak: April 2021 update
- Prof. Jonathan Temte
-
16. ABO blood groups and SARS-CoV-2 susceptibility
- Dr. Sean Stowell
-
17. Impact of COVID-19 on neuropsychiatric disorders and mental health
- Prof. Anthony David
-
18. The immune system response to the SARS-CoV-2 virus: March 2021 update
- Prof. Paul Klenerman
-
23. SARS-CoV-2 vaccine rollout campaigns
- Prof. Luis Graca
-
25. Interspecies transmission of SARS-CoV-2
- Dr. Dalan Bailey
-
26. Complement activation in COVID-19
- Prof. Jeffrey Laurence
-
27. Human movement patterns and local spread of COVID-19
- Prof. Ben Cowling
-
28. SARS-CoV-2 mutations: phenotypes and implications for vaccine development
- Prof. David Montefiori
- 2020
-
29. The immune system response to the SARS-CoV-2 virus: December 2020 update
- Prof. Paul Klenerman
-
30. Triage and end of life care planning in COVID-19
- Prof. Robin Taylor
-
31. Natural killer cells as COVID-19 therapy
- Dr. Philippa Kennedy
-
32. Update on the SNG001 drug, an INFβ therapy for COVID-19
- Prof. Stephen Holgate
-
34. Identification of a new coronavirus-specific RNA export protein complex
- Dr. Montse Bárcena-Martin
-
35. The neurological symptoms of COVID-19
- Dr. Michael Zandi
-
36. Imperial College London’s saRNA Vaccine - COVAC1
- Dr. Katrina Pollock
-
37. Interferon-α2b as a therapy for COVID-19
- Prof. Eleanor N. Fish
-
38. Potential long-term health effects of a SARS-CoV-2 infection
- Prof. Danny Altmann
-
39. The COVID-19 coronavirus outbreak: October 2020 update
- Prof. Jonathan Temte
-
41. Rheumatic diseases and COVID-19
- Dr. Zachary Wallace
-
42. The cardiovascular complications of SARS-CoV-2 infection
- Prof. Srihari Naidu
-
43. Medical wearable devices for tracking symptoms of COVID-19
- Prof. John Rogers
-
44. Risk of re-emergence of COVID-19 after exit from lockdown
- Dr. Leonardo Lopez
-
45. The evolutionary origin of SARS-CoV-2
- Dr. Feng Gao
-
46. Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge
- Prof. Jordan Peccia
-
47. Approaches for elucidating genetic susceptibility to SARS-CoV-2
- Dr. Kenneth Baillie
-
48. The immune system response to the SARS-CoV-2 virus: July 2020 update
- Prof. Paul Klenerman
-
49. The impact of COVID-19 in the elderly and in care homes
- Dr. David Strain
-
50. Human challenge trials for vaccines against COVID-19
- Prof. Peter Smith
-
51. The development of SARS-CoV-2 vaccines
- Prof. Peter Hotez
-
52. Convalescent plasma therapy as a treatment for COVID-19
- Dr. Manu Shankar-Hari
-
53. Remdesivir COVID-19 clinical trial
- Prof. Mahesh Parmar
-
54. Nanotechnologies in the fight against coronaviruses
- Prof. Sabine Szunerits
-
55. The COVID-19 coronavirus outbreak: May 2020 update
- Prof. Jonathan Temte
-
56. INFβ therapy for COVID-19: the new SNG001 drug
- Prof. Stephen Holgate
-
57. Strategies for exiting the lockdown
- Prof. David McCoy
-
58. SARS-CoV-2 human monoclonal antibody therapy
- Prof. James Crowe
-
59. An FDA approved salivary test for SARS-CoV-2 infection
- Prof. Andrew Brooks
-
60. Development of an intranasal vaccine for SARS-CoV-2
- Dr. Scot Roberts
-
61. The immune system response to the SARS-CoV-2 virus: an update
- Prof. Paul Klenerman
-
62. A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2
- Prof. Changchun Liu
-
63. Development of PRO-140 (Leronlimab) as a treatment for COVID-19
- Dr. Jacob Lalezari
-
64. COVID-19 epidemiology and potential treatments: follow up interview
- Prof. Ralph Baric
-
65. SARS-CoV-2 vaccine development: where are we now?
- Prof. Gary Kobinger
-
66. SARS-CoV-2: What we need to know and possible future therapies
- Prof. Stanley Perlman
-
67. SARS-CoV-2 vaccine: current biological targets and considerations
- Dr. Adolfo Garcia-Sastre
-
68. The current understanding of the biology of the SARS-CoV-2 virus
- Prof. Peter Palese
-
70. The immune system response to the SARS-CoV-2 virus
- Prof. Paul Klenerman
-
71. SARS-CoV-2 vaccine development
- Prof. Stanley Plotkin
-
72. The COVID-19 outbreak: an update on the SARS-CoV-2 virus
- Prof. Ralph Baric
-
73. The COVID-19 coronavirus outbreak: a current view
- Prof. Jonathan Temte
-
74. The COVID-19 coronavirus outbreak: March 2020 update
- Prof. Jonathan Temte
Topics Covered
- Approach to modelling future of COVID-19 using historical seasonal Coronavirus data
- Endemic season Coronaviruses (HCoVs) in the population
- Differences between immunological responses to SARS-CoV-2 versus seasonal HCoVs
- Potential evolution of the COVID-19 pandemic
- Transfer of COVID-19 to endemicity
- Continued vigilance towards SARS-CoV-2 in the post-pandemic world
Biography
The speaker's biography will be added shortly.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Antia, R. (2021, March 20). Comparison of COVID-19 and seasonal HCoV pathologies and transfer to endemic state [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 26, 2024, from https://hstalks.com/bs/4607/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Rustom Antia has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Rustom Antia, thank you very much for
taking the time to do this interview with us today to discuss
the similarities and differences in the pathology of SARS-CoV-2 and
other coronaviruses, and discuss the subsequent transfer
of COVID-19 from pandemic to endemic disease.
First of all, could you provide us with some background to the research
you recently published in the journal 'Science', where you
applied immunological dynamics and epidemiological data of
endemic coronaviruses to model
the possible future evolution of the ongoing SARS-CoV-2 pandemic?
What was the initial question that you were attempting to answer?
Prof. Antia: Thank you. Our research integrates the immunological characteristics of virus infections,
such as the duration of immune memory and
how much previous infection reduces pathology following subsequent infections,
to better understand the transmission of the virus in the population.
We proposed to apply this approach to better understand the dynamics
of the endemic human coronaviruses and in particular SARS-CoV-2.
Interviewer: What does your analysis show about the ways in which
endemic coronaviruses infect human populations?
Prof. Antia: There are four strains of endemic human coronaviruses, serological
data show that individuals get infected early
in childhood and these infections are generally mild.
We know this because they develop
antibodies typically by the time they are about four years old.
We also looked at the data and found that it appears that individuals get infected
Hide